{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T02:43:41Z","timestamp":1790304221179,"version":"4.1.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,1,31]],"date-time":"2024-01-31T00:00:00Z","timestamp":1706659200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,1,31]],"date-time":"2024-01-31T00:00:00Z","timestamp":1706659200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Innere Medizin"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1007\/s00108-024-01665-8","type":"journal-article","created":{"date-parts":[[2024,1,31]],"date-time":"2024-01-31T16:02:22Z","timestamp":1706716942000},"page":"407-413","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Immunglobulin-A-Nephropathie \u2013 neue therapeutische M\u00f6glichkeiten","Immunoglobulin\u00a0A nephropathy\u2014New treatment possibilities"],"prefix":"10.1007","volume":"65","author":[{"given":"Matthias","family":"Girndt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,31]]},"reference":[{"key":"1665_CR1","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1056\/NEJMra1206793","volume":"368","author":"RJ Wyatt","year":"2013","unstructured":"Wyatt\u00a0RJ, Julian\u00a0BA (2013) IgA nephropathy. N\u00a0Eng J Med 368:2402\u20132414","journal-title":"N Eng J Med"},{"key":"1665_CR2","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/kisup.2012.9","volume":"2","author":"-","year":"2012","unstructured":"Kidney Disease Improving Global Outcome Initiative (2012) KDIGO Clinical Practice Guideline for Glomerulonephritis. Kidney Int Suppl 2:139\u2013274","journal-title":"Kidney Int Suppl"},{"key":"1665_CR3","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1038\/ki.2009.243","volume":"76","author":"DC Cattran","year":"2009","unstructured":"Cattran\u00a0DC, Coppo\u00a0R, Cook\u00a0HT, Feehally\u00a0J, Roberts\u00a0ISD, Troyanov\u00a0S, Alpers\u00a0CE, Amore\u00a0A, Barratt\u00a0J, Berthoux\u00a0F, Bonsib\u00a0S, Bruijn\u00a0JA, D\u2019Agati\u00a0V, D\u2019Amico\u00a0G, Emancipator\u00a0S, Emma\u00a0F, Ferrario\u00a0F, Fervenza\u00a0FC, Florquin\u00a0S, Fogo\u00a0A, Geddes\u00a0CC, Groene\u00a0H\u2011J, Haas\u00a0M, Herzenberg\u00a0AM, Hill\u00a0PA, Hogg\u00a0RJ, Hsu\u00a0SI, Jennette\u00a0JC, Joh\u00a0K, Julian\u00a0BA, Kawamura\u00a0T, Lai\u00a0FM, Leung\u00a0CB, Li\u00a0L\u2011S, Li\u00a0PKT, Liu\u00a0Z\u2011H, Mackinnon\u00a0B, Mezzano\u00a0S, Schena\u00a0FP, Tomino\u00a0Y, Walker\u00a0PD, Wang\u00a0H, Weening\u00a0JJ, Yoshikawa\u00a0N, Zhang\u00a0H (2009) The oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. Kidney Int 76:534\u2013545","journal-title":"Kidney Int"},{"key":"1665_CR4","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1046\/j.1523-1755.2001.0590031077.x","volume":"59","author":"Y Hiki","year":"2001","unstructured":"Hiki\u00a0Y, Odani\u00a0H, Takahashi\u00a0M, Yasuda\u00a0Y, Nishimoto\u00a0A, Iwase\u00a0H, Shinzato\u00a0T, Kobayashi\u00a0Y, Maeda\u00a0K (2001) Mass spectrometry proves under-O-glycosylation of glomerular IgA1 in IgA nephropathy. Kidney Int 59:1077\u20131085","journal-title":"Kidney Int"},{"key":"1665_CR5","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1681\/ASN.2012010053","volume":"23","author":"F Berthoux","year":"2012","unstructured":"Berthoux\u00a0F, Suzuki\u00a0H, Thibaudin\u00a0L, Yanagawa\u00a0H, Maillard\u00a0N, Mariat\u00a0C, Tomino\u00a0Y, Julian\u00a0BA, Novak\u00a0J (2012) Autoantibodies targeting galactose-deficient IgA1 associate with progression of IgA nephropathy. J\u00a0Am Soc Nephrol 23:1579\u20131587","journal-title":"J Am Soc Nephrol"},{"key":"1665_CR6","doi-asserted-by":"publisher","first-page":"3177","DOI":"10.1681\/ASN.2007050526","volume":"18","author":"HN Reich","year":"2007","unstructured":"Reich\u00a0HN, Troyanov\u00a0S, Scholey\u00a0JW, Cattran\u00a0DC (2007) Remission of proteinuria improves prognosis in IgA nephropathy. J\u00a0Am Soc Nephrol 18:3177\u20133183","journal-title":"J Am Soc Nephrol"},{"key":"1665_CR7","doi-asserted-by":"publisher","unstructured":"Herrington WG, Staplin N, Wanner C, Green JB, Hauske SJ, Emberson JR, Preiss D, Judge P, Mayne KJ, Ng SYA, Sammons E, Zhu D, Hill M, Stevens W, Wallendszus K, Brenner S, Cheung AK, Liu Z\u2011H, Li J, Hooi LS, Liu W, Kadowaki T, Nangaku M, Levin A, Cherney D, Maggioni AP, Pontremoli R, Deo R, Goto S, Rossello X, Tuttle KR, Steubl D, Petrini M, Massey D, Eilbracht J, Brueckmann M, Landray MJ, Baigent C, Haynes R (2023) Empagliflozin in patients with chronic kidney disease. N Eng J Med. 388(2):117-127 https:\/\/doi.org\/10.1056\/NEJMoa2204233","DOI":"10.1056\/NEJMoa2204233"},{"key":"1665_CR8","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.kint.2021.03.033","volume":"100","author":"DC Wheeler","year":"2021","unstructured":"Wheeler\u00a0DC, Toto\u00a0RD, Stef\u00e1nsson\u00a0BV, Jongs\u00a0N, Chertow\u00a0GM, Greene\u00a0T, Hou\u00a0FF, McMurray\u00a0JJV, Pecoits-Filho\u00a0R, Correa-Rotter\u00a0R, Rossing\u00a0P, Sj\u00f6str\u00f6m\u00a0CD, Umanath\u00a0K, Langkilde\u00a0AM, Heerspink\u00a0HJL (2021) A\u00a0pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy. Kidney Int 100:215\u2013224","journal-title":"Kidney Int"},{"key":"1665_CR9","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1016\/S0140-6736(22)02074-8","volume":"400","author":"-","year":"2022","unstructured":"SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists\u2019 Consortium\u00a0(2022) Impact of diabetes on the effects of sodium glucose co-transporter-2\u00a0inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. Lancet 400:1788\u20131801","journal-title":"Lancet"},{"key":"1665_CR10","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1038\/ki.2014.143","volume":"86","author":"DE Kohan","year":"2014","unstructured":"Kohan\u00a0DE, Barton\u00a0M (2014) Endothelin and endothelin antagonists in chronic kidney disease. Kidney Int 86:896\u2013904","journal-title":"Kidney Int"},{"key":"1665_CR11","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1016\/S0140-6736(23)00569-X","volume":"401","author":"HJL Heerspink","year":"2023","unstructured":"Heerspink\u00a0HJL, Radhakrishnan\u00a0J, Alpers\u00a0CE, Barratt\u00a0J, Bieler\u00a0S, Diva\u00a0U, Inrig\u00a0J, Komers\u00a0R, Mercer\u00a0A, Noronha\u00a0IL, Rheault\u00a0MN, Rote\u00a0W, Rovin\u00a0B, Trachtman\u00a0H, Trimarchi\u00a0H, Wong\u00a0MG, Perkovic\u00a0V (2023) Sparsentan in patients with IgA nephropathy: a\u00a0prespecified interim analysis from a\u00a0randomised, double-blind, active-controlled clinical trial. Lancet 401:1584\u20131594","journal-title":"Lancet"},{"key":"1665_CR12","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.1056\/NEJMoa1415463","volume":"373","author":"T Rauen","year":"2015","unstructured":"Rauen\u00a0T, Eitner\u00a0F, Fitzner\u00a0C, Sommerer\u00a0C, Zeier\u00a0M, Otte\u00a0B, Panzer\u00a0U, Peters\u00a0H, Benck\u00a0U, Mertens\u00a0PR, Kuhlmann\u00a0U, Witzke\u00a0O, Gross\u00a0O, Vielhauer\u00a0V, Mann\u00a0JFE, Hilgers\u00a0R\u2011D, Floege\u00a0J (2015) Intensive supportive care plus immunosuppression in IgA nephropathy. N\u00a0Eng J Med 373:2225\u20132236","journal-title":"N Eng J Med"},{"key":"1665_CR13","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1016\/j.kint.2020.04.046","volume":"98","author":"T Rauen","year":"2020","unstructured":"Rauen\u00a0T, Wied\u00a0S, Fitzner\u00a0C, Eitner\u00a0F, Sommerer\u00a0C, Zeier\u00a0M, Otte\u00a0B, Panzer\u00a0U, Budde\u00a0K, Benck\u00a0U, Mertens\u00a0PR, Kuhlmann\u00a0U, Witzke\u00a0O, Gross\u00a0O, Vielhauer\u00a0V, Mann\u00a0JFE, Hilgers\u00a0R\u2011D, Floege\u00a0J (2020) After ten years of follow-up, no difference between supportive care plus immunosuppression and supportive care alone in IgA nephropathy. Kidney Int 98:1044\u20131052","journal-title":"Kidney Int"},{"key":"1665_CR14","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1001\/jama.2022.5368","volume":"327","author":"J Lv","year":"2022","unstructured":"Lv\u00a0J, Wong\u00a0MG, Hladunewich\u00a0MA, Jha\u00a0V, Hooi\u00a0LS, Monaghan\u00a0H, Zhao\u00a0M, Barbour\u00a0S, Jardine\u00a0MJ, Reich\u00a0HN, Cattran\u00a0D, Glassock\u00a0R, Levin\u00a0A, Wheeler\u00a0DC, Woodward\u00a0M, Billot\u00a0L, Stepien\u00a0S, Rogers\u00a0K, Chan\u00a0TM, Liu\u00a0Z\u2011H, Johnson\u00a0DW, Cass\u00a0A, Feehally\u00a0J, Floege\u00a0J, Remuzzi\u00a0G, Wu\u00a0Y, Agarwal\u00a0R, Zhang\u00a0H, Perkovic\u00a0V (2022) Effect of oral methylprednisolone on decline in kidney function or kidney failure in patients with IgA nephropathy: the TESTING randomized clinical trial. JAMA 327:1888\u20131898","journal-title":"JAMA"},{"key":"1665_CR15","doi-asserted-by":"publisher","first-page":"224","DOI":"10.14227\/DT300423P224","volume":"30","author":"J Dressman","year":"2023","unstructured":"Dressman\u00a0J (2023) Comparative dissolution of Budesonide from four commercially available products for oral administration: implications for interchangeablity. Dissolution Technol 30:224\u2013229","journal-title":"Dissolution Technol"},{"key":"1665_CR16","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1016\/S0140-6736(17)30550-0","volume":"389","author":"BC Fellstr\u00f6m","year":"2017","unstructured":"Fellstr\u00f6m\u00a0BC, Barratt\u00a0J, Cook\u00a0H, Coppo\u00a0R, Feehally\u00a0J, de Fijter\u00a0JW, Floege\u00a0J, Hetzel\u00a0G, Jardine\u00a0AG, Locatelli\u00a0F, Maes\u00a0BD, Mercer\u00a0A, Ortiz\u00a0F, Praga\u00a0M, S\u00f8rensen\u00a0SS, Tesar\u00a0V, Del Vecchio\u00a0L (2017) Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a\u00a0double-blind, randomised, placebo-controlled phase\u00a02b\u00a0trial. Lancet 389:2117\u20132127","journal-title":"Lancet"},{"key":"1665_CR17","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/S0140-6736(23)01554-4","volume":"402","author":"R Lafayette","year":"2023","unstructured":"Lafayette\u00a0R, Kristensen\u00a0J, Stone\u00a0A, Floege\u00a0J, Tesa\u0159\u00a0V, Trimarchi\u00a0H, Zhang\u00a0H, Eren\u00a0N, Paliege\u00a0A, Reich\u00a0HN, Rovin\u00a0BH, Barratt\u00a0J (2023) Efficacy and safety of a\u00a0targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2\u2011year results from a\u00a0randomised phase\u00a03\u00a0trial. Lancet 402:859\u2013870","journal-title":"Lancet"},{"key":"1665_CR18","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1681\/ASN.2014101000","volume":"26","author":"N Maillard","year":"2015","unstructured":"Maillard\u00a0N, Wyatt\u00a0RJ, Julian\u00a0BA, Kiryluk\u00a0K, Gharavi\u00a0A, Fremeaux-Bacchi\u00a0V, Novak\u00a0J (2015) Current understanding of the role of complement in IgA nephropathy. J\u00a0Am Soc Nephrol 26:1503\u20131512","journal-title":"J Am Soc Nephrol"},{"key":"1665_CR19","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1016\/j.ekir.2020.08.003","volume":"5","author":"RA Lafayette","year":"2020","unstructured":"Lafayette\u00a0RA, Rovin\u00a0BH, Reich\u00a0HN, Tumlin\u00a0JA, Floege\u00a0J, Barratt\u00a0J (2020) Safety, tolerability and efficacy of narsoplimab, a\u00a0novel MASP\u20112 inhibitor for the treatment of IgA nephropathy. Kidney Int Rep 5:2032\u20132041","journal-title":"Kidney Int Rep"},{"key":"1665_CR20","doi-asserted-by":"publisher","unstructured":"Zhang H, Rizk DV, Perkovic V, Maes B, Kashihara N, Rovin B, Trimarchi H, Sprangers B, Meier M, Kollins D, Papachristofi O, Milojevic J, Junge G, Nidamarthy PK, Charney A, Barratt J (2024) Results of a randomized double-blind placebo-controlled Phase 2 study propose iptacopan as an alternative complement pathway inhibitor for IgA nephropathy. Kidney Int. 105(1):189-199 https:\/\/doi.org\/10.1016\/j.kint.2023.09.027","DOI":"10.1016\/j.kint.2023.09.027"},{"key":"1665_CR21","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1016\/j.ekir.2023.01.041","volume":"8","author":"DV Rizk","year":"2023","unstructured":"Rizk\u00a0DV, Rovin\u00a0BH, Zhang\u00a0H, Kashihara\u00a0N, Maes\u00a0B, Trimarchi\u00a0H, Perkovic\u00a0V, Meier\u00a0M, Kollins\u00a0D, Papachristofi\u00a0O, Charney\u00a0A, Barratt\u00a0J (2023) Targeting the alternative complement pathway with Iptacopan to treat IgA nephropathy: design and rationale of the APPLAUSE-IgAN study. Kidney Int Rep 8:968\u2013979","journal-title":"Kidney Int Rep"},{"key":"1665_CR22","doi-asserted-by":"publisher","unstructured":"Mathur M, Barratt J, Chacko B, Chan TM, Kooienga L, Oh K\u2011H, Sahay M, Suzuki Y, Wong MG, Yarbrough J, Xia J, Pereira BJG (2024) A phase 2 trial of sibeprenlimab in patients with IgA nephropathy. N Eng J Med. 390(1):20-31 https:\/\/doi.org\/10.1056\/NEJMoa2305635","DOI":"10.1056\/NEJMoa2305635"}],"container-title":["Die Innere Medizin"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-024-01665-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00108-024-01665-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-024-01665-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,22]],"date-time":"2024-03-22T11:03:07Z","timestamp":1711105387000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00108-024-01665-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,31]]},"references-count":22,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["1665"],"URL":"https:\/\/doi.org\/10.1007\/s00108-024-01665-8","relation":{},"ISSN":["2731-7080","2731-7099"],"issn-type":[{"value":"2731-7080","type":"print"},{"value":"2731-7099","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,31]]},"assertion":[{"value":"5 January 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"M.\u00a0Girndt gibt an, Forschungsf\u00f6rderung oder Vortragshonorare ohne Bezug zum Thema von folgenden Unternehmen erhalten zu haben: Amgen GmbH, Astellas GmbH, Bayer AG, Boehringer-Ingelheim GmbH, GSK GmbH, MSD Pharma GmbH, Sanofi GmbH.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}